Text Size

Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment

Geerling, G.; Hamada, S.; Trocmé, S.; Ræder, S.; Chen, X.; Fassari, C.; Lanzl, I.


  • 2022
  • Ophthalmology and therapy
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Department of Ophthalmology, University Hospital Düsseldorf, Düsseldorf, Germany; Queen Victoria Hospital, East Grinstead, UK; Aleris Specialistvård Sabbatsberg, Europakliniken Department of Ophthalmology, Sabbatsbergs Hospital, Stockholm, Sweden; The Norwegian Dry Eye Clinic, Oslo, Norway; Santen SA, Geneva, Switzerland; Chiemsee Augentagesklinik, Prien, Germany

Related Publications

Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study

Ishikawa H., Oka K., Inoue H.


Tear Biomarkers of Topical Sirolimus in Meibomian Gland Dysfunction: A Randomized Trial

Zhou L.; Shimizu H.; Togashi Y.; Kirihara T.; Yang Y.; Lam C.T.; Shimada H.; Tong L.


Layer-by-layer tear film measurement in patients with dry eye and meibomian gland dysfunction

Arita R., Takeuchi G., Sasai K., Nakamura M., Akiba M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022